T. Rowe Price Associates’s TG Therapeutics TGTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Shares
Change %
Capital Flow Portfolio Weight Portfolio Position
2025
Q2
$55.7M Buy
1,547,544
+1,157,016
+296% +$41.6M 0.01% 701
2025
Q1
$15.4M Buy
390,528
+93,427
+31% +$3.68M ﹤0.01% 1013
2024
Q4
$8.94M Buy
297,101
+215,601
+265% +$6.49M ﹤0.01% 1167
2024
Q3
$1.91M Sell
81,500
-6,421
-7% -$150K ﹤0.01% 1663
2024
Q2
$1.57M Buy
87,921
+2,318
+3% +$41.3K ﹤0.01% 1686
2024
Q1
$1.3M Buy
85,603
+5,015
+6% +$76.3K ﹤0.01% 1779
2023
Q4
$1.38M Buy
80,588
+27,249
+51% +$466K ﹤0.01% 1714
2023
Q3
$446K Sell
53,339
-244,700
-82% -$2.05M ﹤0.01% 2158
2023
Q2
$7.4M Buy
298,039
+223,545
+300% +$5.55M ﹤0.01% 1120
2023
Q1
$1.12M Sell
74,494
-18,172
-20% -$273K ﹤0.01% 1730
2022
Q4
$1.1M Sell
92,666
-11,917
-11% -$141K ﹤0.01% 1728
2022
Q3
$620K Buy
104,583
+4,326
+4% +$25.6K ﹤0.01% 2012
2022
Q2
$426K Sell
100,257
-480,718
-83% -$2.04M ﹤0.01% 2278
2022
Q1
$5.53M Sell
580,975
-17
-0% -$162 ﹤0.01% 1449
2021
Q4
$11M Sell
580,992
-844,156
-59% -$16M ﹤0.01% 1395
2021
Q3
$47.4M Sell
1,425,148
-458,503
-24% -$15.3M ﹤0.01% 1031
2021
Q2
$73.1M Buy
1,883,651
+266,310
+16% +$10.3M 0.01% 896
2021
Q1
$78M Buy
1,617,341
+216,496
+15% +$10.4M 0.01% 848
2020
Q4
$72.9M Buy
1,400,845
+1,349,836
+2,646% +$70.2M 0.01% 830
2020
Q3
$1.37M Buy
+51,009
New +$1.37M ﹤0.01% 1673
2018
Q4
Sell
-39,297
Closed -$220K 2581
2018
Q3
$220K Buy
39,297
+349
+0.9% +$1.95K ﹤0.01% 2429
2018
Q2
$512K Sell
38,948
-788
-2% -$10.4K ﹤0.01% 2126
2018
Q1
$564K Sell
39,736
-13,000
-25% -$185K ﹤0.01% 2036
2017
Q4
$432K Buy
52,736
+38,000
+258% +$311K ﹤0.01% 2128
2017
Q3
$175K Hold
14,736
﹤0.01% 2422
2017
Q2
$148K Buy
14,736
+36
+0.2% +$362 ﹤0.01% 2433
2017
Q1
$171K Hold
14,700
﹤0.01% 2425
2016
Q4
$68K Hold
14,700
﹤0.01% 2499
2016
Q3
$114K Buy
+14,700
New +$114K ﹤0.01% 2429